Super League Gaming Inc.(SLE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLE Super League Gaming Inc.

Closed Good Friday 04-17 16:00:00 EDT

0.2370

+0.0160

+7.24%

盘后0.2443

+0.0073+3.08%

19:15 EDT

High0.2375	Low0.2210	Vol22.01K
Open0.2300	D1 Closing0.2210	Amplitude7.47%
Mkt Cap4.21M	Tradable Cap2.95M	Total Shares17.78M
T/O4.98K	T/O Rate0.18%	Tradable Shares12.43M
P/B24.78	ROE-327.46%	EPS-2.35
52wk High1.74	52wk Low0.1700	P/E-0.10
Dividend0.00	Div.Yield0.00	ROA-57.03%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":0.237,"timestamp":1744920000000,"preClose":0.221,"halted":0,"volume":22013,"hourTrading":{"tag":"盘后","latestPrice":0.2443,"preClose":0.237,"latestTime":"19:15 EDT","volume":1128,"amount":262.64759,"timestamp":1744931706966},"delay":0,"floatShares":12432329,"shares":17776170,"eps":-2.351262,"marketStatus":"Closed Good Friday","change":0.016,"latestTime":"04-17 16:00:00 EDT","open":0.23,"high":0.2375,"low":0.221,"amount":4979.9182211199995,"amplitude":0.074661,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.351262,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":0.221,"postHourTrading":{"tag":"盘后","latestPrice":0.2443,"preClose":0.237,"latestTime":"19:15 EDT","volume":1128,"amount":262.64759,"timestamp":1744931706966},"volumeRatio":0.32542524227282105},"requestUrl":"/m/hq/s/SLE","defaultTab":"news","newsList":[{"id":"2527015440","title":"Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015440","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015440?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 22:42","pubTimestamp":1744728120,"startTime":"0","endTime":"0","summary":"Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy  designation to its investigational pipeline candidate FT819 for the treatment of active moderate to severe systemic lupus erythematosus , including lupus nephritis.The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application.FT819 is an off-the-shelf, iPSC-derived CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The latest RMAT designation by the FDA underlines the potential of FT819 to address an area of significant unmet medical needs.Year to date, shares of Fate Therapeutics have plunged 44% comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-lupus-candidate-ft819-144200510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","BK4532","BK4533","IE00BN0W2V16.EUR","JAZZ","IE00BN0W2W23.USD","LU0823416689.USD","SLE","IE00BN0W2T93.GBP","LU0320765992.SGD","FATE","LU0889565916.HKD","BK4077","KRYS","LU0109394709.USD","BK4007","BK4139"],"gpt_icon":0},{"id":"2527549951","title":"Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527549951","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527549951?lang=en_us&edition=full_marsco","pubTime":"2025-04-14 20:00","pubTimestamp":1744632000,"startTime":"0","endTime":"0","summary":"– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process. – RMAT review by FDA included initial clinical safety and activity data from ongoing Phase 1 study of FT819 in SLE. SAN DIEGO, April 14, 2025  -- Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell -derived off-the-shelf cellular immunotherapies to patients, today announced that the U.S. Food and Drug Administration  granted Regenerative Medicine Advanced Therapy  designation to FT819, an investigational, off-the-shelf, iPSC-derived CAR T-cell therapy in Phase 1 clinical development for the treatment of active moderate to severe systemic lupus erythematosus , including lupus nephritis .The RMAT designation was established under the 21st Century Cures Act to expedite the development and review of regenerative medicine therapies for serious","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-receives-regenerative-medicine-120000379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEIS","BK4139","IE00B19Z4B17.USD","SLE","IE0031619046.USD","FATE","BK4077","IE00B66KJ199.SGD","BK4157","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2526384049","title":"Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526384049","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526384049?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy. Dr. Banerjee added, \"Artiva is leading the development of NK cell treatments for autoimmune disease, with the potential to offer a much-needed, long-term therapeutic option with an accessibility and safety profile that enables broad use in a community setting. The robust B-cell depletion seen with AlloNK through enhanced antibody-directed killing of cells in non-Hodgkin lymphoma bodes well for our opportunity to deeply deplete B-cells in patients with autoimmune diseases and to bring about meaningful clinical improvements and medication reductions. Artiva has built a very seasoned development team, and I am excited to lead the effort to further define the indications where AlloNK can be most impactful, and to help drive the program towards late-stage development.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARTV","BK4077","BK4022","IIM","R","BMS","RA","SLE","BK4232"],"gpt_icon":0},{"id":"2525318890","title":"FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2525318890","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525318890?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 18:46","pubTimestamp":1744109160,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune diseases — systemic lupus erythematosus , idiopathic inflammatory myopathy  and diffuse systemic sclerosis .How Does the Fast Track Tag Benefit ALLO’s Drug Development?Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, meet an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’。In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to a profit of 25 cents. During the same timeframe, estimates for loss per share for 2026 have","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-three-fast-track-104600523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B5TLWC47.USD","BK4505","BK4585","SLE","BK4567","CTMX","BK4007","BK4588","ETNB","BK4077","ANIP","ALLO","BK4139","IE00BFXG0V08.USD","IIM","IE00BYQQ9H92.USD","FAST","BK4104"],"gpt_icon":0},{"id":"2525048864","title":"Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma","url":"https://stock-news.laohu8.com/highlight/detail?id=2525048864","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525048864?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 20:30","pubTimestamp":1744029000,"startTime":"0","endTime":"0","summary":"Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therape","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056719/0/en/Allogene-Granted-Three-U-S-FDA-Fast-Track-Designations-FTD-for-ALLO-329-a-Next-Generation-Dual-Targeted-CD19-CD70-Allogeneic-CAR-T-for-the-Treatment-of-Lupus-Myositis-and-Scleroder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5TLWC47.USD","CAR","BK4022","BK4505","ALLO","BK4139","BK4585","FAST","IE00BYQQ9H92.USD","BK4077","IE00BFXG0V08.USD","BK4104","IIM","BK4567","SLE","BK4230","BK4588"],"gpt_icon":0},{"id":"2525732917","title":"Super League Enterprise Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2525732917","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525732917?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 02:59","pubTimestamp":1743793184,"startTime":"0","endTime":"0","summary":"We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqCM:SLE Earnings and Revenue History April 4th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 11%. Earnings per share  also missed analyst estimates by 20%.Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Interactive Media and Services industry in the US.Performance of the American Interactive Media and Services industry.The company's shares are down 41% from a week ago.We should say that we've discovered 5 warning signs for Super League Enterprise (3 don't sit too well with us!) that you should be aware of before investing here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-full-2024-185944978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE"],"gpt_icon":0},{"id":"2524419418","title":"Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524419418","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524419418?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"LONDON, April  01, 2025  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation progra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053144/0/en/Autolus-Therapeutics-to-Host-R-D-Investor-Event-on-Wednesday-April-23-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","BK4588","HST","BK4218","LENZ","BK4181","BK4585","BK4139"],"gpt_icon":0},{"id":"2523926560","title":"Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523926560","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523926560?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 21:20","pubTimestamp":1743427200,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International, Inc.CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet needs. The discovery marks the first using Logica, an artificial intelligence -powered drug development solution that translates biological insights into optimized preclinical assets.Alongside Valo Health and Flagship Pioneering’s in-house drug development unit, Pioneering Medicines, Charles River looks forward to further leveraging the power of Logica to advance this program into lead optimization.Importance of Charles River and Valo’s Combined Offering. Logica, the result of a strategic collaboration between Charles River and Valo Health, is the industry’s first computation-powered, unified target-to-candidate offering. The platform leverages the integration of Valo Health’s AI-powered Opal Computational Platform and Charles River’s leading expertise in drug discov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/charles-river-valo-healths-logica-132000618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","LU0957791311.USD","LU1989771016.USD","BK4504","BK4535","LU1914381329.SGD","BK4548","IE00BFTCPJ56.SGD","LU2211815571.USD","TMO","IE00BJJMRZ35.SGD","ABT","LU2764262908.HKD","BK4585","LU0096362180.USD","LU2125909593.SGD","LU1633808545.USD","LU2092937221.SGD","BK4077","LU1721429402.USD","LU1670628061.USD","LU0640476718.USD","LU1791710400.SGD","LU1923621640.USD","LU2041044095.USD","CRL","SG9999004303.SGD","SLE","LU2468319806.SGD","SG9999002232.USD","LU2764263039.SGD","LU1691799644.USD","LU1854103824.USD","LU1712237335.SGD","LU2211814178.USD","IE00B2B36J28.USD","LU2298321311.HKD","IE0009355771.USD","LU1548497426.USD","BK4533","LU2125909247.SGD","BIO","BK4530","BK4568","LU1023059063.AUD","IE00B19Z8X17.USD","LU2764263203.CNY","LU0234572021.USD","LU1983299246.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2523094592","title":"GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094592?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Marc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052210/0/en/GRI-Bio-Bolsters-Intellectual-Property-Portfolio-with-Granting-of-Two-Global-Patents-for-Europe-and-Japan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4077","SLE","BK4007","GRI"],"gpt_icon":0},{"id":"2523171969","title":"Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523171969","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523171969?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET clinical development program since ACR C","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052139/0/en/Cabaletta-Bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1668664300.SGD","IE00BKVL7J92.USD","LU1989772840.SGD","LU1074936037.SGD","CABA","LU0320765646.SGD","LU0971096721.USD","SLE","LU2347655156.SGD","LU0314104364.USD","LU1989772923.USD","LU0795875086.SGD","LU1720051108.HKD","BK4534","LU0106831901.USD","LU2133065610.SGD","LU0098860793.USD","LU2111349929.HKD","IE00BZ1G4Q59.USD","BK4127","LU0158827781.USD","LU0912757837.SGD","BK4504","LU2089283258.USD","LU0795875169.SGD","LU0158827948.USD","LU1363072403.SGD","LU1162221912.USD","BK4588","LU0267386448.USD","LU2023251221.USD","BK4563","LU1548497426.USD","BK4585","BK4581","LU2089284900.SGD","LU0225283273.USD","LU2271345857.HKD","LU2028103732.USD","IMNM","LU1720051017.SGD","BK4516","LU0006306889.USD","CDMO","LU1732799900.SGD","BK4077","LU2357305700.SGD","LU1732800096.USD","LU0106261372.USD"],"gpt_icon":0},{"id":"2523119796","title":"Super League Enterprise Inc (SLE) Q4 2024 Earnings Call Highlights: Strategic Shifts and Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2523119796","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523119796?lang=en_us&edition=full_marsco","pubTime":"2025-03-30 03:01","pubTimestamp":1743274886,"startTime":"0","endTime":"0","summary":"Revenue Diversification: Positive signs in Q1 with revenue diversification kicking in.Margins: Margins are recovering with higher-margin products added to the portfolio.Active Pursuits: Approximately $20 million in active pursuits across 77 unique programs.EBITDA Goal: Aim to be EBITDA positive in Q4.Cost Structure: Aggressively attacking cost structure to align with breakeven imperative.GuruFocus has detected 6 Warning Signs with SLE.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Super League Enterprise Inc  is optimistic about optimizing its business model to deliver meaningful shareholder value despite facing micro-cap and macroeconomic challenges.Revenue diversification is underway, with mobile games becoming a significant growth area, contributing to 16% of revenue in Q4 and expected to reach 20% in Q1.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-inc-sle-190126765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","RBLX"],"gpt_icon":0},{"id":"2522577543","title":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522577543","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522577543?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:31","pubTimestamp":1743168675,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings SummarySuper League Enterprise Inc SLE.OQ reported a quarterly adjusted loss of 45 cents per share for the quar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB14L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2522508032","title":"Super League Enterprise (SLE) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522508032","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522508032?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:40","pubTimestamp":1743165602,"startTime":"0","endTime":"0","summary":"Super League Enterprise  came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $3.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -28.57%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.54, delivering a surprise of -92.86%.Super League Enterprise , which belongs to the Zacks Gaming industry, posted revenues of $3.43 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 31.48%. This compares to year-ago revenues of $9.51 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Super League Enterprise shares have lost about 35.9% since the beginning of the year versus the S&P 500's decline of -3.2%.While Super League Enterprise has underperformed the market so far this year, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-sle-reports-124002934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LVS","SLE"],"gpt_icon":0},{"id":"2522784175","title":"BRIEF-Super League Enterprise President Matt Edelman Promoted To Role Of Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522784175","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522784175?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:49","pubTimestamp":1743162555,"startTime":"0","endTime":"0","summary":"BRIEF-Super League Enterprise President Matt Edelman Promoted To Role Of Chief Executive OfficerMarch 28 (Reuters) - Super League Enterprise Inc SLE.O:SUPER LEAGUE ENTERPRISE INC - PRESIDENT MATT EDEL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2522520479","title":"Super League Enterprise Q4 2024 Adj EPS $(0.29) Misses $(0.26) Estimate, Sales $3.43M Miss $5.50M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520479","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520479?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:35","pubTimestamp":1743161727,"startTime":"0","endTime":"0","summary":"Super League Enterprise (NASDAQ:SLE) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.26) by 11.54 percent. This is a 61.33 percent increase over losses of $(0.75) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44533697/super-league-enterprise-q4-2024-adj-eps-0-29-misses-0-26-estimate-sales-3-43m-miss-5-50m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2522520124","title":"Super League Enterprise Inc - President Matt Edelman Promoted to Role of Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520124?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:31","pubTimestamp":1743161503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2522252043","title":"Super League Enterprise Inc - Qtrly Shr Loss $0.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2522252043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522252043?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:31","pubTimestamp":1743161503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2522123520","title":"Super League Enterprise Inc - Ann Hand to Support Strategic Alternative Initiatives as Executive Chair;","url":"https://stock-news.laohu8.com/highlight/detail?id=2522123520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522123520?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:31","pubTimestamp":1743161503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2522520528","title":"Press Release: Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520528","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520528?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues. Ann Hand to Support Strategic Alternative Initiatives as Executive Chair; President Matt Edelman Promoted to the Role of Chief Executive Officer. Renowned Marketing and Advertising Executive Bant Breen Appointed to Board of Directors. SANTA MONICA, Calif., March 28, 2025  -- Super League , a leader in redefining the gaming industry as a media channel, today released fourth quarter and full year 2024 financial results.In an effort to bolster our Board, we are thrilled to appoint Bant Breen as a Director. Bant is a noted marketing and media executive, entrepreneur and academic. Specifically, Bant has spent a vast amount of his career in holding company and operating leadership roles with some of the largest global ad","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","AAQC"],"gpt_icon":0},{"id":"2522184495","title":"Dow Dips 150 Points Following Trump's Auto Tariffs, Verint Systems Slides On Q4 Miss: Greed Index Remains In 'Fear' Zone","url":"https://stock-news.laohu8.com/highlight/detail?id=2522184495","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522184495?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 14:08","pubTimestamp":1743142102,"startTime":"0","endTime":"0","summary":"U.S. markets closed lower on Thursday due to tariff news, with little change in the CNN Fear &amp; Greed index. S&amp;P 500 and Nasdaq also fell.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44529927/dow-dips-150-points-following-trumps-auto-tariffs-verint-systems-slides-on-q4-miss-greed-index-remains-in-fear-zone","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ","MBGAF","BK4099","QLD","NVIW.SI","USJW.SI","MNQmain","KPLT","BK4122","SLE","NQmain","SNX","TQQQ","BK4140","TSYW.SI","QID","LU1559883803.SGD","BK4166","USAW.SI","VRNT","BK4077","PSQ","BK4023","POAHF","PCOM","LU0566484027.USD",".IXIC"],"gpt_icon":1}],"profile":{"websiteUrl":"http://superleague.com","stockEarnings":[{"period":"1week","weight":0.0724},{"period":"1month","weight":-0.3229},{"period":"3month","weight":-0.6108},{"period":"6month","weight":-0.7476},{"period":"1year","weight":-0.8257},{"period":"ytd","weight":-0.6162}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Super League Gaming, Inc. builds and operates networks of games, monetization tools, and content channels across metaverse gaming platforms that empower developers, energize players, and entertain fans. The company's solutions provide access to an audience consisting of players in the metaverse environments, fans of various gaming influencers, and viewers of gameplay content across social media and digital video platforms. The company's platform includes access to in-game communities, a metaverse advertising platform, and a network of highly viewed channels and original shows on Instagram, TikTok, Snap, YouTube, and Twitch, as well as cloud-based livestream production tools and an esports invitational tournament series. Its properties also deliver opportunities for brands and advertisers to achieve insights and marketing outcomes with gamers of various ages. The company was formerly known as Nth Games, Inc. and changed its name to Super League Gaming, Inc. in June 2015. The company was incorporated in 2014 and is headquartered in Santa Monica, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.229878},{"month":2,"riseRate":0.666667,"avgChangeRate":0.021464},{"month":3,"riseRate":0.142857,"avgChangeRate":0.010938},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.127505},{"month":5,"riseRate":0.5,"avgChangeRate":0.000336},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.117833},{"month":7,"riseRate":0.166667,"avgChangeRate":0.008333},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.227827},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.222702},{"month":10,"riseRate":0.5,"avgChangeRate":0.019868},{"month":11,"riseRate":0.5,"avgChangeRate":-0.024283},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.058588}],"exchange":"NASDAQ","name":"Super League Gaming Inc.","nameEN":"Super League Gaming Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Super League Gaming Inc.(SLE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Super League Gaming Inc.(SLE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Super League Gaming Inc.,SLE,Super League Gaming Inc.股票,Super League Gaming Inc.股票老虎,Super League Gaming Inc.股票老虎国际,Super League Gaming Inc.行情,Super League Gaming Inc.股票行情,Super League Gaming Inc.股价,Super League Gaming Inc.股市,Super League Gaming Inc.股票价格,Super League Gaming Inc.股票交易,Super League Gaming Inc.股票购买,Super League Gaming Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Super League Gaming Inc.(SLE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Super League Gaming Inc.(SLE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction